MedPath

Development of the Oncology Opportunity Cost Assessment Tool

Completed
Conditions
Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Behavioral: Focus Group
Other: Interview
Other: Research or Clinical Assessment Tool
Registration Number
NCT04694911
Lead Sponsor
Thomas Jefferson University
Brief Summary

This study develops and tests an instrument to measure opportunity costs called the Oncology Opportunity Cost Assessment Tool (OOCAT) in cancer patients. Patients experience significant costs, both direct financial as well as indirect costs, associated with seeking cancer treatment. While the direct financial impact of care on patients is receiving increased attention, other important consequences, such as opportunity cost, remain largely unmeasured. Opportunity cost is an economics term that refers to the loss of potential benefits from other options when one option is chosen - if resources are used for one purpose, they are no longer available for the next best option. The information and knowledge gained from this study may help researchers develop the OOCAT, which may allow them to understand the opportunity cost of treatment for each patient. The OOCAT may then be used to determine not just the best medications for patients, but also the best comprehensive treatment plan that will allow them to get the right treatment in the right place at the right time.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
40
Inclusion Criteria
  • Treated for cancer at one of the 3 participating sites (Jefferson Center City, Jefferson Methodist Hospital, Jefferson Abington)
  • English speaking
  • Able to attend and participate in a focus group
Exclusion Criteria
  • Treated at a Jefferson site other than the ones mentioned
  • Non-English Speaking

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Health Services Research (focus group, interview, OOCAT)Focus GroupFOCUS GROUP: Patients participate in focus group session over 60-90 minutes. COGNITIVE INTERVIEW: Patients complete cognitive interview on the clarity, interpretability, and ease of use of the OOCAT. FEASIBILITY TESTING: Patients receive OOCAT at the point of care, online, or via telephone, per patients' preference.
Health Services Research (focus group, interview, OOCAT)InterviewFOCUS GROUP: Patients participate in focus group session over 60-90 minutes. COGNITIVE INTERVIEW: Patients complete cognitive interview on the clarity, interpretability, and ease of use of the OOCAT. FEASIBILITY TESTING: Patients receive OOCAT at the point of care, online, or via telephone, per patients' preference.
Health Services Research (focus group, interview, OOCAT)Research or Clinical Assessment ToolFOCUS GROUP: Patients participate in focus group session over 60-90 minutes. COGNITIVE INTERVIEW: Patients complete cognitive interview on the clarity, interpretability, and ease of use of the OOCAT. FEASIBILITY TESTING: Patients receive OOCAT at the point of care, online, or via telephone, per patients' preference.
Primary Outcome Measures
NameTimeMethod
Implementation of OOCAT1 Day of OOCAT administration

Will test the instrument as developed with patients receiving oncology care across the Jefferson Health System to gather preliminary data informing the reliability of the scale to measure opportunity cost of seeking care.

Patient-level opportunity costs associated with oncology care1 Day of Interview

Patient-identified themes that contribute to opportunity cost will be generated via patient focus groups

Development of the Oncology Opportunity Cost Assessment Tool (OOCAT)1 Day of Interview

Will organize themes into domains and will generate items representing each of the themes for inclusion in an instrument designed to measure patient opportunity cost of seeking care. Will perform cognitive interviews with a random sampling of patients from the cancer center to test initial instrument items to ensure content validity and clarity of each item.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Sidney Kimmel Cancer Center at Thomas Jefferson University

🇺🇸

Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath